Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 21, 2014; 20(27): 8796-8806
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.8796
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.8796
Table 2 Response rates for lubiprostone 12 wk phase III irritable bowel syndrome with constipation studies
| Lubiprostone | Placebo | P value | |
| Overall responder | 17.90% | 10.10% | 0.001 |
| Month 1 | 10.80% | 7.50% | 0.078 |
| Month 2 | 18.20% | 11.40% | 0.003 |
| Month 3 | 22.00% | 14.50% | 0.003 |
- Citation: Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR. Irritable bowel syndrome: A concise review of current treatment concepts. World J Gastroenterol 2014; 20(27): 8796-8806
- URL: https://www.wjgnet.com/1007-9327/full/v20/i27/8796.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i27.8796